The International
LungCancerSummit
Where Leaders in Thoracic Oncology UniteAgainst Lung Cancer||To Share Knowledge||To Exchange||To Debate||To Advance Care||To Fight Cancer||To Drive Progress||To Provide Insights
Your invitation · 2 min
A word from our faculty
Choose your calendar
Google Calendar (Online)
Outlook Calendar (Offline)
Outlook On Microsoft Office 365 (Online)
Outlook On The Web (Online)
Apple Offline Calendar / iCalHave a case for our expert roundtables? Submit it →
Led by global experts
The people in the room
A global roster of oncologists, surgeons and pathologists, chaired from Lausanne and drawn from across the field.
Solange Peters
Chair, Switzerland
Alfredo Addeo
Chair, Switzerland
Millie Das
USA
Hidehito Horinouchi
Japan
Telma Sequeira
Portugal
Christine Lovly
USA
David Planchard
France
Sandip Patel
USA
Alessio Cortellini
Italy
Lauren Byers
USA
Giannis Mountzios
Greece
Anne-Marie Dingemans
Netherlands
The programme · 13 Nov 2026
CME-certified
Expert-Driven Education & Insights
A day built around what changes practice
Debate · which is the better choice in 1L ES-SCLC?
Panel · open questions & patient cases
All speakers & attendeesJoin us on 13 November
Free for healthcare professionals · 5 + 5 CME credits · Lausanne or live online
Where we meet · Lausanne
On site & online
Hosted at CHUV in Lausanne and live-streamed worldwide. Join in person, or from your own clinic.
ILCS · In frames
ILCS 2025, in Lausanne
A day on the ground with the faculty, the debate and the room between sessions.
Partners & supporters
Backed, independently
The ILCS is supported by 18 industry partners, with no influence on the content.
For sponsoring opportunities, please contact us at sponsoring@lungsummit.org
Beyond the summit
Year-round education
The summit doesn’t stop in November. Watch every ILCS session on demand, plus webinars, expert debates and interviews, released all year and CME-certified.
Live & upcoming
Upcoming events
Live symposia, webinar series and new interviews between summits, released and CME-certified all year.
Coming soon · 09:45 CET · Lausanne + Live online
The International Lung Cancer Summit 2026
Chairs
Speakers
MillieDas
HidehitoHorinouchi
TelmaSequeira
ChristineLovly
DavidPlanchard
SandipPatel
AlessioCortellini
LaurenByers
GiannisMountzios
Anne-MarieDingemansChoose your calendar
The library
Watch on demand
Featured sessions
Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi
Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.
Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro
Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.
Expert Insights
2025 Approvals & Highlights
1 h 49 min
Reshaping Approaches in SCLC with the Latest Advances in LS- and ES-Disease
34 min
Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond
32 min
The Reading Room
Tarlatamab added to durvalumab maintenance improved OS in extensive-stage SCLC
HARMONi primary analysis reports 6.8 against 4.4 months PFS for ivonescimab plus chemotherapy after EGFR TKI progression
Pleural metastases carried worse two-year survival than contralateral lung metastases in stage M1a NSCLC
An EGFR-SHC1 fusion resists EGFR inhibitors through its non-kinase partner
Akeso reports an OS benefit for ivonescimab over pembrolizumab in PD-L1-positive NSCLC
AI-HOPE registry recruits 920 patients to build machine-learning models for metastatic NSCLC outcomes
Adjuvant alectinib held its advantage in ALINA’s Asia subgroup, on 31 events and immature survival data
International panel sets 55 consensus recommendations for managing Dato-DXd side effects in NSCLC
Two EORTC questionnaires cover the common side effects in NSCLC labels, and miss 62 rarer ones
Fewer patients discontinued adjuvant alectinib than chemotherapy in ALINA, and quality-of-life gains held to two years
Cleared ctDNA within weeks predicted longer survival on immunotherapy in a 109-patient study
SLFN11 expression across lung neuroendocrine neoplasms: highest in SCLC, and prognostic only there
A ctDNA tumour fraction of 5 percent or more marks the patients who benefit from adding chemotherapy to checkpoint blockade
AIOT expert panel endorses chemo-immunotherapy as a new standard in resectable stage II-III NSCLC
Pre-surgical ctDNA clearance reached 66% with neoadjuvant nivolumab against 38% with placebo in CheckMate 77T
Radiation plus durvalumab without chemotherapy cleared its survival target in frail LA-NSCLC patients
EGFR amplification at baseline marks shorter time on first-line osimertinib, in exon 19 deletions but not L858R
EVOKE-01 biomarker analysis: Trop-2 staining did not pick out who does better on sacituzumab govitecan than docetaxel
ORCHARD final data: osimertinib plus gefitinib gives modest benefit in EGFR C797X, and the authors advise against further study
Adjuvant crizotinib did not prolong DFS in resected ALK-positive NSCLC
Watch every session on demand
Free for healthcare professionals. One account opens every session, webinar and interview.
Find your area
Browse by topic
Patient Cases
Let us discuss your patient in our expert roundtables
Submit an anonymised case or a question. The faculty take it up live at our webinars and at ILCS. The questions you carry into clinic, answered by the people writing the guidelines.
Stay in the room
Join our network in thoracic oncology
One email when there is something new. Sessions, the next roundtable, the next live event.